Fig. 4
From: HIIT and MICT mitigate endothelial dysfunction in early atherosclerotic mice via PCSK9 inhibition
PCSK9 impairs endothelial function through activating the TRX/TXNIP/NLRP3/GSDMD-N signaling pathway. (A and B) Protein expressions of TRX, TXNIP, NLRP3, and GSDMD-N were analyzed by western blotting in Vehicle- or PCSK9-treated aortas in vitro. MCC950 (a specific NLRP3 inhibitor), TXNIP-IN-1 (a specific TXNIP inhibitor), and Ruscogenin (another TXNIP inhibitor) were applied, with a final intervention concentration of 10 μg/ml for all inhibitors. (C and D) The protein expressions of TRX, TXNIP, NLRP3 and GSDMD-N were detected by western blot. (E) ACh-induced and (F) SNP-induced vasodilation in vitro of aortas treated with or without PCSK9. *P < 0.05, Vehicle group compared with PCSK9 group. Data are presented as means ± SD.
